A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease

DOI: 10.1038/s41375-019-0700-9
Leukemia, 2020, 34, 1775-1786.

#	Paper	IF	Citations
37	Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic. *British Journal of Clinical Pharmacology*, **2020**, 86, 1790-1792	3.8	2
36	Hydroxychloroquine reduces IL-6 and pro-thrombotic status. *Autoimmunity Reviews*, **2020**, 19, 102555	13.6	3
35	Emerging agents that target signaling pathways in cancer stem cells. *Journal of Hematology and Oncology*, **2020**, 13, 60	22.4	51
34	Is it beneficial to use hydroxychloroquine and imatinib combination in order to achieve deeper molecular responses in patients with chronic myeloid leukemia?. *Leukemia*, **2020**, 34, 3426-3427	10.7	0
33	Comment on "Cheilitis with hemorrhagic crusts of the vermilion lips". *International Journal of Dermatology*, **2020**, 59, e244-e245	1.7	
32	Unfolded Protein Response in Leukemia: From Basic Understanding to Therapeutic Opportunities. *Trends in Cancer*, **2020**, 6, 960-973	12.5	5
31	Safety of hydroxychloroquine in COVID-19 and other diseases: a systematic review and meta-analysis of 53 randomized trials. *European Journal of Clinical Pharmacology*, **2021**, 77, 13-24	2.8	9
30	Chronic Myeloid Leukemia: A Model Disease of the Past, Present and Future. *Cells*, **2021**, 10,	7.9	19
29	Xenograft models for pediatric cancer therapies. *Faculty Reviews*, **2021**, 10, 11	1.2	1
28	Eradicating residual chronic myeloid leukaemia: basic research lost in translation. *Lancet Haematology,the*, **2021**, 8, e101-e104	14.6	
27	Recent advances in understanding chronic myeloid leukemia: where do we stand?. *Faculty Reviews*, **2021**, 10, 35	1.2	2
26	Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	6
25	Autophagy based cellular physiological strategies target oncogenic progression. *Journal of Cellular Physiology*, **2021**,	7	1
24	Pharmacologic targeting of the P-TEFb complex as a therapeutic strategy for chronic myeloid leukemia. *Cell Communication and Signaling*, **2021**, 19, 83	7.5	1
23	ULK1 inhibition promotes oxidative stress-induced differentiation and sensitizes leukemic stem cells to targeted therapy. *Science Translational Medicine*, **2021**, 13, eabd5016	17.5	2
22	Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. *Blood Reviews*, **2021**, 49, 100825	11.1	9
21	Recent progress of autophagy signaling in tumor microenvironment and its targeting for possible cancer therapeutics. *Seminars in Cancer Biology*, **2021**,	12.7	5

20	Autophagy in hematopoiesis and leukemogenesis. **2022**, 125-141		0
19	Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	5
18	The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases. *Current Pharmaceutical Design*, **2020**, 26, 4467-4485	3.3	17
17	Loss of SMARCB1 promotes autophagy and facilitates tumour progression in chordoma by transcriptionally activating ATG5. *Cell Proliferation*, **2021**, e13136	7.9	1
16	Treatment-Free Remission in Chronic Myeloid Leukemia and New Approaches by Targeting Leukemia Stem Cells. *Frontiers in Oncology*, **2021**, 11, 769730	5.3	1
15	Systematic review and meta-analysis of the safety of chloroquine and hydroxychloroquine from randomized controlled trials on malarial and non-malarial conditions. *Systematic Reviews*, **2021**, 10, 294	3	0
14	Autophagy in Cancer Therapy-Molecular Mechanisms and Current Clinical Advances. *Cancers*, **2021**, 13,	6.6	0
13	Understanding the Role of Autophagy in Cancer Formation and Progression Is a Real Opportunity to Treat and Cure Human Cancers. *Cancers*, **2021**, 13,	6.6	4
12	Use of SRS microscopy for imaging drugs. **2022**, 403-419		0
11	Nanoprodrug ratiometrically integrating autophagy inhibitor and genotoxic agent for treatment of triple-negative breast cancer.. *Biomaterials*, **2022**, 283, 121458	15.6	2
10	The multifaceted role of autophagy in cancer.. *EMBO Journal*, **2022**, e110031	13	5
9	NRBF2 regulates the chemoresistance of small cell lung cancer by interacting with the P62 protein in the autophagy process. *IScience*, **2022**, 104471	6.1	0
8	Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia. *Cancers*, **2022**, 14, 3300	6.6	0
7	Systematic Review of Psychiatric Adverse Effects Induced by Chloroquine and Hydroxychloroquine: Case Reports and Population Studies. 106002802211135		0
6	EXABS-156-CML Beyond TKI Therapy in CML. **2022**, 22, S61-S63		0
5	Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. **2022**, 7,		1
4	The role of autophagy in colorectal cancer: Impact on pathogenesis and implications in therapy. 9,		2
3	A Critical Review of Chloroquine and Hydroxychloroquine as Potential Adjuvant Agents for Treating People with Cancer. **2022**, 2, 431-443		0

2	The SAR and action mechanisms of autophagy inhibitors that eliminate drug resistance. **2022**, 244, 114846	0
1	What Is the Significance of Lysosomal-Mediated Resistance to Imatinib?. **2023**, 12, 709	0